Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $299.04 million. The enterprise value is $232.06 million.

Market Cap	299.04M
Enterprise Value	232.06M

Important Dates

The last earnings date was Thursday, November 7, 2024, before market open.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 12.18 million shares outstanding. The number of shares has increased by 548.42% in one year.

Current Share Class	12.18M
Shares Outstanding	12.18M
Shares Change (YoY)	+548.42%
Shares Change (QoQ)	+0.94%
Owned by Insiders (%)	0.62%
Owned by Institutions (%)	30.37%
Float	5.09M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	16.29
P/TBV Ratio	16.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.53, with a Debt / Equity ratio of 1.21.

Current Ratio	6.53
Quick Ratio	6.23
Debt / Equity	1.21
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-59.53

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-61.10%
Return on Capital (ROIC)	-214.37%
Revenue Per Employee	n/a
Profits Per Employee	-$1.64M
Employee Count	37
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Q32 Bio has paid $1.88 million in taxes.

Income Tax	1.88M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +143.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+143.60%
50-Day Moving Average	43.94
200-Day Moving Average	30.42
Relative Strength Index (RSI)	16.31
Average Volume (20 Days)	102,958

Short Selling Information

The latest short interest is 686,073, so 5.63% of the outstanding shares have been sold short.

Short Interest	686,073
Short Previous Month	678,638
Short % of Shares Out	5.63%
Short % of Float	13.47%
Short Ratio (days to cover)	3.65

Income Statement

In the last 12 months, Q32 Bio had revenue of -$14.66 million and -$60.61 million in losses. Loss per share was -$5.76.

Revenue	-14.66M
Gross Profit	-60.60M
Operating Income	-77.39M
Pretax Income	-65.02M
Net Income	-60.61M
EBITDA	-76.89M
EBIT	-77.39M
Loss Per Share	-$5.76

Full Income Statement

Balance Sheet

The company has $89.08 million in cash and $22.10 million in debt, giving a net cash position of $66.97 million or $5.50 per share.

Cash & Cash Equivalents	89.08M
Total Debt	22.10M
Net Cash	66.97M
Net Cash Per Share	$5.50
Equity (Book Value)	18.30M
Book Value Per Share	1.51
Working Capital	79.52M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$67.00 million and capital expenditures -$73,000, giving a free cash flow of -$67.07 million.

Operating Cash Flow	-67.00M
Capital Expenditures	-73,000
Free Cash Flow	-67.07M
FCF Per Share	-$5.51

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	527.79%
Pretax Margin	400.58%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-548.42%
Shareholder Yield	-548.42%
Earnings Yield	-20.27%
FCF Yield	-22.43%

Analyst Forecast

The average price target for Q32 Bio is $72.33, which is 194.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$72.33
Price Target Difference	194.62%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Q32 Bio has an Altman Z-Score of -2.12 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.12
Piotroski F-Score	2